The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 4:05 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #20. Agenus 4-Antibody

Acquirer: Agenus (NASDAQ:AGEN)
Acquiree: 4-Antibody
Details: Agenus Inc. (NASDAQ:AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

Agenus is a clinical-stage immuno-oncology company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Co. is also developing its proprietary anti-CTLA-4 antibody, AGEN1181, which is designed to expand the population of patients benefiting from anti-CTLA-4 therapy. Co.'s AgenTus Therapeutics, Inc. subsidiary focuses on allogeneic cell therapies.

AGEN SEC Filing Email Alerts Service


Open the AGEN Page at The Online Investor »

Company Name: 
Agenus Inc
Website: 
www.agenusbio.com
Sector: 
Biotechnology
Number of ETFs Holding AGEN: 
22
Total Market Value Held by ETFs: 
$60.25M
Total Market Capitalization: 
$544.00M
% of Market Cap. Held by ETFs: 
11.07%
 

Open the AGEN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
99th percentile
(ranked higher than approx. 99% of all stocks covered)

Analysts' Target Price:
AGEN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 20 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.